Division of Hematology & Oncology
Richard D. Lopez, MD Print E-mail

Rank: lopez_richard-2008
Associate Professor 

Division:
Hematology & Oncology

Campus Address: WTI 5

Mailing Address:
1720 2nd Avenue South, WTI 5                            
Birmingham, AL 35294-3300

Phone: (205) 934-1908

Email: rlopez@uabmc.edu


For an appointment, call (205) 934-9999 or toll free 1 (800) UAB-8816.


Departmental Affiliation(s):
Primary: Medicine
Secondary: Pathology

Medical School:
Stanford University School of Medicine, Stanford, CA

Internal Medicine Residency:
Stanford University School of Medicine, Stanford, CA

Fellowships:
Medical Oncology, Stanford University School of Medicine, Stanford, CA

Clinical and Research Fellow, Bone Marrow Transplantation, Stanford University School of Medicine, Stanford, CA

Certifications:
Board certified in Medical Oncology


Clinical Interests:
Bone marrow transplantation

Research Interests:
(1) Experimental Immunotherapy: Development of animal models to examine how the innate anti-tumor properties of γδ-T cells might be exploited for the adoptive cellular immunotherapy of cancer.

(2) Experimental Clinical Immunotherapy: Development of the corresponding human models (clinical trials) intended to introduce human -T cells – either in the autologous or allogeneic setting – as a form of therapy for a variety of malignant or infectious diseases.

(3) Experimental Clinical Hematopoietic Stem Cell Transplantation: Adapting standard non-myeloablative allogeneic hematopoietic stem cell (HSC) transplantation for use as a clinical platform for the experimental cell-based immunotherapies described above.


Selected Publications:

Lopez RD, Xu S, Guo B, Negrin RS and Waller EK. CD2-mediated IL-12-dependent signals render human γδ-T cells resistant to mitogen-induced apoptosis, permitting the large scale ex vivo expansion of functionally distinct lymphocytes: Implications for the development of adoptive immunotherapy strategies. Blood 96:3827-3837, 2000.

Lopez RD, Waller EK, Lu P-H, Negrin RS. CD58/LFA-3 and IL-12 provided by activated monocytes are critical in the in vitro expansion and function of CD56+ T Cells: Cancer Immunology and Immunotherapy 49:629-640, 2001.

Guo B, Hollmig KH and Lopez RD. Down-regulation of IL-2 receptor a (CD25) characterizes human γδ-T cells rendered resistant to apoptosis after CD2 engagement in the presence of IL-12. Cancer Immunology and Immunotherapy. 50:625-637, 2002.

Lopez RD. Human γδ-T cells in adoptive immunotherapy of malignant and infectious diseases. Immunologic Research 26:207-221, 2002.

Lamb LS, Lopez RD. γδ-T cells: A new frontier for immunotherapy. Biology of Blood and Marrow Transplantation 11:161-168, 2005.

Liu Z, Guo BL, Gehrs BC, Nan L and Lopez RD. Ex vivo expanded human Vg9Vd2+ γδ-T cells mediate innate antitumor activity against human prostate cancer cells in vitro. Journal of Urology. 173:1552-1556, 2005.

Guo BL, Liu Z, Aldrich WA and Lopez RD. Innate anti-breast cancer immunity of apoptosis-resistant human γδ-T cells. Breast Cancer Research and Treatment. 93:169-175, 2005.

Lopez RD. Exploiting the Innate Antitumor Properties of γδ-T Cells for the Immunotherapy of Human Cancer. The Hematologist (American Society of Hematology News and Reports, Invited Mini Review). July/August 2007.

Liu Z, Eltoum I-E, Guo BL, Beck B and Lopez RD. Protective immunosurveillance and therapeutic antitumor activity of γδ-T cells demonstrated in a mouse model of prostate cancer. Journal of Immunology 180:6044-6053, 2008.

Liu Z, Guo BL and Lopez RD. Expression of ICAM-1 or ICAM-2 is critical in determining sensitivity of pancreatic cancer cells to cytolysis by human γδ-T cells: Implications in the design of γδ-T cell-based immunotherapies for pancreatic cancer. Journal of Gastroenterology and Hepatology (in press).

Publications: See a listing of publications on PubMed, a service of the National Library of Medicine.